- About Us
- Nano-Social Network
- Nano Consulting
- My Account
May 23rd, 2005
Jack Uldrich: In February, pSivida (Nasdaq: PSDV), an Australian-based company specializing in biomedical applications of nanotechnology, began trading on the Nasdaq as an American Depositary Receipt (ADR). In its first three months on Wall Street, it promptly fell from a high of $10 a share to just over $4.
Since that time, however, pSivida's stock has risen by more than 65%. It currently trades at around $7.
Will it continue to rise? I believe so, and I base that answer on three recent developments.
|Related News Press|
Strength of hair inspires new materials for body armor January 18th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016